TMB (Tumor Mutational Burden)

Cell experiments revealed that interference of UBE2Q1-AS1 significantly inhibited the proliferation and migration of 786-O cells. The migrasome-associated lncRNA model accurately predicts ccRCC patient prognosis, offering new insights for immunotherapy and clinical applications.

In conclusion, quantitative GC-related histology of nrLNs can serve as a prognostic indicator for MSI-H CRC. Our findings suggest that GC-activated nrLNs may represent B cell-mediated antitumor immunity, independent of tumor-infiltrating T cells and tumor-intrinsic molecular characteristics.

Radiology plays a central role in the management of these therapies, as phenomena such as pseudoprogression challenge the classic RECIST (response evaluation criteria in solid tumors) system, and early detection of immune-mediated side effects often precedes clinical manifestation in imaging. The growing complexity of therapy requires radiologists to possess precise image interpretation, interdisciplinary collaboration, and knowledge of immunological principles, thus, enabling an improved prognosis for many tumor types.

It highlights the importance of understanding tumour-immune interactions in their full biological context, and explores current thinking on how to reshape the immune landscape of solid tumours. By addressing both immunological and physical barriers, future approaches may broaden the benefit of immunotherapy beyond its current scope, ultimately improving outcomes for patients with traditionally treatment-resistant cancers.

In summary, the genomic distinctions now suggest that a proportion of SMMs with progressor phenotype are akin to MM, whereas nonprogressor SMM has monoclonal gammopathy of undetermined significance-like characteristics. The results should influence further investigation in larger studies to inform future diagnostic criteria and trial designs.

This study classified BC by mRNAsi-related genes and established corresponding risk models. The findings of the present study propose a novel classification tool based on stem cell characteristics, which has the potential to be employed for prognostic stratification in BC patients and to offer guidance for developing personalised treatment strategies.

We established a DRRG-based prognostic model for CRC and uncovered their links to metabolic regulation, immune infiltration, and metastasis. These findings highlight DRRGs as potential biomarkers and therapeutic targets and suggest that DR-mimicking strategies may benefit CRC management.

These genes were also found to be associated with tumor mutational burden (TMB) and microsatellite instability (MSI) scores. Our findings reveal how these genes contribute to CRC pathogenesis by modulating the immune microenvironment, providing important biomarkers and targets for the development of novel therapeutic strategies.

We identified ANGPT2, CRIPT, GLA, LMNB1, and MARVELD3 as potential tumor antigens. Our study implies that IS2 phenotype might benefit from mRNA vaccination.

The cooperative GOG 281/LOGS trial showed that trametinib, an MEK inhibitor (MEKi), was significantly more effective than standard-of-care options (including chemotherapy or hormonal therapy) in increasing progression-free survival (median PFS 13.0 months vs. 7.2 months; hazard ratio 0.48, p < 0.001)...Genomic and multi-omic profiling have revealed actionable vulnerabilities and precision oncology approaches. The advent of biomarker-directed trials, molecular subtyping incorporation, and innovative computational strategies is likely to gradually ameliorate therapy selection and, thereby, finally improve long-term outcomes for patients with this complex disease.

pDCs appear to exert a tumor-promoting, immune-evasive role, suggesting that DC function depends on their programming and tumor context. Selective targeting of DC subsets may offer novel therapeutic opportunities in TP53-mutated, low-TMB cancers.

We demonstrate that optimal efficacy requires biomarker-guided patient selection integrating genetic and TME features, precise sequencing, and a mechanistic understanding of drug-specific immunomodulatory effects. The integration of platform trial designs (I-SPY2, CheckMate-7FL) with composite biomarker algorithms represents a paradigm shift toward precision neoadjuvant immunotherapy, offering a conceptual framework for transforming outcomes in molecularly defined HR+ breast cancer subsets.